Sample size calculation
The sample size was calculated to be 160 patients per treatment arm, assuming 80% statistical power, a 5% significance level, and that the most efficacious treatment would result in adequate control of heartburn in 60% of patients after 4 weeks. A difference of 15% points between the treatments was considered clinically significant.
The participating primary care physicians in the Norwegian Heartburn Study Group were:
Bjørn O Bache, Inger Bjurstrøm, Jens Brovold, Hans Braadland, Åge Dahl, Frode Flobak, Bjørn O Flaaten, Eivind Fristad, Olav Gaupen, Thomas Gladewitz, Ove Grønlie, Ole P Halvorsen, Åge N Hansen, Inge Haslerud, Henry Helvig, Kjell Hjelle, Bernt-H Høgsæt, Hans Høvik, Arne G Haanshuus, Harald Jomaas, Bjørg Jordet, Arild Kaisen, Odd E Karlsen, Alf Kimsås, Aslak N Knutsen, Pål Kristensen, Margarete Krog, Jan Laugen, Svein Lunde, Ingard Løge, Per H Madsen, Randi Medhus, Jan Melby, Geir Moe, Herman Myrland, Stein Nilsen, Tor Nilsen, Dag Nordhaug, Paal Norheim, Jostein Norvold, Per A Oppegaard, Mansour Parsi, Per Sandbakken, Robert Sillerud, Knut Spikkeland, Odd K Starheim, Ragnar Stene, Ragnhild Strand, Sigurd Thomle, Bernt E Tylden, Ivar H Udnæs, Jan-Richard Unnvik, Kolbjørn Valnes, Inger Viervoll Knoph, Hans B Visdal Johnsen, Audun Visted, Per O Walle, Erik L Werner, Ole A Ystgaard, and Anders O Aaserud. The participating gastroenterologists were: Ståle Barstad, Fred A Halvorsen, Jan G Hatlebakk, Kristian Hveem, Ole Høie, Gjermund Johnsen, Kjell Kannelønning, Bjørn Moum, Morten Mowé, and Tor M Omland.
Rapid Responses:
Read all Rapid Responses
- PPI Prescribing - is Omeprazole really the right choice?
- Alexander Williams
- bmj.com, 20 Sep 1999 [Full text]